Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone/Acetaminophen for acute migraine treatment
NCT05685225Phase 2Withdrawn
- Sponsor
- Allodynic Therapeutics
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Naltrexone + Acetaminophen in migraine, sponsored by Allodynic Therapeutics. Planned start Jan 2025; status: withdrawn.
02
Drugs
Naltrexone + Acetaminophen
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05685225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685225.